ArticleCancer research2023

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.

Yige Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.